StocksMedium•4 November 2026•
1 min read
Rhythm Pharmaceuticals Secures $750 Million Financing from KKR and Blackstone
Key Facts
1Rhythm Pharmaceuticals announced a new $750 million financing package to support IMCIVREE commercialization and MC4R pipeline programs.
2The financing package consists of a term loan provided by KKR's HealthCare Royalty and Blackstone.
Rhythm Pharmaceuticals announced a new $750 million financing package to support IMCIVREE commercialization and its developmental programs. Yahoo Finance reported that the financing consists of a term loan provided by KKR's HealthCare Royalty and Blackstone to advance the company's MC4R pathway programs.
Rhythm Pharmaceuticals shares closed at $86.44 on November 3, 2026, while Blackstone closed at $118.19 on the same date. KKR shares recorded a close of $95.99 on November 3, 2026, as these institutional lenders move to support the company's commercial expansion in the biotech sector.